Trial reportThe Journal of clinical endocrinology and metabolism2011
Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.
Trial report in The Journal of clinical endocrinology and metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 76 citations in OpenAlex.
- Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone.The Journal of clinical endocrinology and metabolism · 2016Trial
- Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Trial
- Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial.The Journal of clinical endocrinology and metabolism · 2012Trial
- Reexamination of pharmacokinetics of oral testosterone undecanoate in hypogonadal men with a new self-emulsifying formulation.Journal of andrologyTrial
- Discordance Between Online Information and Male Hypogonadism Clinical Guidelines: A Global Multilingual Content Analysis.The Journal of clinical endocrinology and metabolism · 2026Article
- From bench to bedside: the evolution and future of prostate-specific antigen testing.Medical oncology (Northwood, London, England) · 2025Review
- Elevated periprostatic androgens, sneaky testosterone and its implications.Nature reviews. Urology · 2024Review
- Effects of Androgen Treatment on Growth in Patients with 5-α-Reductase Type 2 Deficiency.Journal of personalized medicine · 2023Article
- Consequence of evolutionary loss of seasonal breeding by humans for prostate cancer chemoprevention.American journal of clinical and experimental urology · 2023Review
- Androgens, aging, and prostate health.Reviews in endocrine & metabolic disorders · 2022Review
- Review
- Determination of Intraprostatic and Intratesticular Androgens.International journal of molecular sciences · 2021Review
- Proteoglycans in the Pathogenesis of Hormone-Dependent Cancers: Mediators and Effectors.Cancers · 2020Review
- Article
- Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats.Hormones & cancer · 2019Article
- Androgen Signaling in Prostate Cancer.Cold Spring Harbor perspectives in medicine · 2017Review
- Taking the first steps in establishing recommendations for testosterone monitoring in men with prostate cancer on androgen-deprivation therapy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2017Article
- Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.Endocrine reviews · 2017Review
- Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Treatment of Hypogonadism: Current and Future Therapies.F1000Research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
contextConcern exists that androgen treatment might adversely impact prostate health in older men. Dihydrotestosterone (DHT), derived from local conversion of testosterone to DHT by 5α-reductase enzymes, is the principal androgen within the prostate. Exogenous androgens raise serum DHT concentrations, but their effects on the prostate are not clear.
objectiveTo determine the impact of large increases in serum DHT concentrations on intraprostatic androgen concentrations and androgen action within the prostate.
designDouble-blind, randomized, placebo-controlled.
settingSingle academic medical center.
participants31 healthy men ages 35-55.
interventionDaily transdermal DHT or placebo gel.
main outcome measuresSerum and prostate tissue androgen concentrations and prostate epithelial cell gene expression after 4 wk of treatment.
resultsTwenty-seven men completed all study procedures. Serum DHT levels increased nearly sevenfold, while testosterone levels decreased in men treated with daily transdermal DHT gel but were unchanged in the placebo-treated group (P < 0.01 between groups). In contrast, intraprostatic DHT and testosterone concentrations on d 28 were not different between groups (DHT: placebo = 2.8 ± 0.2 vs. DHT gel = 3.1 ± 0.5 ng/g; T: placebo = 0.6 ± 0.2 vs. DHT gel = 0.4 ± 0.1, mean ± se). Similarly, prostate volume, prostate-specific antigen, epithelial cell proliferation, and androgen-regulated gene expression were not different between groups.
conclusionsRobust supraphysiologic increases in serum DHT, associated with decreased serum T, do not significantly alter intraprostatic levels of DHT, testosterone, or prostate epithelial cell androgen-regulated gene expression in healthy men. Changes in circulating androgen concentrations are not necessarily mimicked within the prostate microenvironment, a finding with implications for understanding the impact of androgen therapies in men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.